Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: Irinotecan
DRUG: Bevacizumab

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]